Ionis Pharmaceuticals (MEX:IONS) Total Current Assets : MXN49,487 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Ionis Pharmaceuticals's total current assets for the quarter that ended in Mar. 2025 was MXN49,487 Mil.

Ionis Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Ionis Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Total Current Assets Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

42,384.02

48,106.34

42,943.72

44,843.47

54,647.98

Ionis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															40,091.16	42,674.54	53,436.52	54,647.98	49,487.00

Ionis Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Ionis Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	47919.224	+	1922.645	+	260.947	+	4545.166
	=	54,648

Ionis Pharmaceuticals's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	43885.949	+	812.334	+	235.31	+	4553.402
	=	49,487

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Ionis Pharmaceuticals (MEX:IONS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Ionis Pharmaceuticals's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	43885.949	-	47815.355	+	0.75 * 0	+	0.5 * 235.31
=	-3,812

Ionis Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.